| Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation M Galluzzo, M Talamonti, C De Simone, S D’Adamio, G Moretta, ... Expert opinion on biological therapy 18 (7), 727-735, 2018 | 68 | 2018 |
| Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature G Caldarola, F Pirro, A Di Stefani, M Talamonti, M Galluzzo, S D’Adamio, ... Expert opinion on biological therapy 20 (6), 665-672, 2020 | 59 | 2020 |
| Alexithymia and plaque psoriasis: preliminary investigation in a clinical sample of 250 patients M Talamonti, M Galluzzo, S Servoli, S D'Adamio, L Bianchi Dermatology 232 (6), 648-654, 2017 | 46 | 2017 |
| Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab M Galluzzo, S D’Adamio, L Bianchi, M Talamonti Journal of Dermatological Treatment 30 (1), 40-44, 2019 | 40 | 2019 |
| In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis M Galluzzo, S D’Adamio, D Silvaggio, P Lombardo, L Bianchi, ... Expert Opinion on Biological Therapy 20 (2), 173-182, 2020 | 38 | 2020 |
| Brodalumab for the treatment of psoriasis M Galluzzo, S D’adamio, L Bianchi, M Talamonti Expert Review of Clinical Immunology 12 (12), 1255-1271, 2016 | 29 | 2016 |
| The role of pharmacogenetics in chronic plaque psoriasis: update of the literature M Talamonti, S D’Adamio, L Bianchi, M Galluzzo Molecular diagnosis & therapy 21, 467-480, 2017 | 24 | 2017 |
| Tofacitinib for the treatment of psoriasis M Galluzzo, S D’Adamio, S Servoli, L Bianchi, S Chimenti, M Talamonti Expert Opinion on Pharmacotherapy 17 (10), 1421-1433, 2016 | 23 | 2016 |
| Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date M Galluzzo, S D’Adamio, A Massaro, A Piccolo, L Bianchi, M Talamonti Clinical, Cosmetic and Investigational Dermatology, 311-321, 2019 | 21 | 2019 |
| Tildrakizumab for treating psoriasis M Galluzzo, S D’adamio, L Bianchi, M Talamonti Expert opinion on biological therapy 17 (5), 645-657, 2017 | 19 | 2017 |
| Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience M Galluzzo, S D’Adamio, D Silvaggio, P Lombardo, A Massaro, CG Egan, ... Expert Opinion on Biological Therapy 20 (1), 95-104, 2020 | 17 | 2020 |
| The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis S D’Adamio, D Silvaggio, P Lombardo, L Bianchi, M Talamonti, ... Expert Opinion on Drug Safety 18 (11), 1031-1041, 2019 | 16 | 2019 |
| A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab M Galluzzo, S D’Adamio, E Campione, S Mazzilli, L Bianchi, M Talamonti Journal of Dermatological Treatment 29 (sup1), 17-20, 2018 | 16 | 2018 |
| Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections M Galluzzo, S D’Adamio, L Bianchi, M Talamonti Expert Opinion on Drug Metabolism & Toxicology 14 (2), 197-206, 2018 | 16 | 2018 |
| Pharmacotherapeutic management of psoriasis in adolescents and children S D’Adamio, D Silvaggio, A Massaro, P Lombardo, L Bianchi, ... Expert Opinion on Pharmacotherapy 20 (14), 1777-1785, 2019 | 15 | 2019 |
| A safety evaluation of guselkumab for the treatment of psoriasis M Galluzzo, S D’Adamio, E Campione, L Bianchi, M Talamonti Expert Opinion on Drug Safety 17 (7), 741-751, 2018 | 15 | 2018 |
| Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients M Galluzzo, S D’Adamio, R Pastorino, A Andreoli, S Servoli, L Bianchi, ... Expert Opinion on Biological Therapy 18 (3), 229-235, 2018 | 15 | 2018 |
| Biologic therapy for acrodermatitis continua of Hallopeau: successful treatment with secukinumab and review of the literature M Galluzzo, S D'Adamio, M Teoli, L Bianchi, M Talamonti Dermatologic Therapy 32 (3), e12899, 2019 | 14 | 2019 |
| Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience F Bardazzi, F Viviani, Y Merli, V Di Lernia, F Peccerillo, A Conti, C Lasagni, ... Expert Opinion on Biological Therapy 22 (12), 1561-1566, 2022 | 12 | 2022 |
| Treating a multidrug-resistant psoriatic HLA-C* 18: 01 allele carrier with combination ustekinumab apremilast therapy M Galluzzo, S D’Adamio, E Campione, L Bianchi, M Talamonti Molecular Diagnosis & Therapy 22, 717-721, 2018 | 11 | 2018 |
